Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 15/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.52 |
| ▸ | FAP | Q12884 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050089 | 1.00 | DPP4 (0.52) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2182923 | 1.00 | DPP4 (0.52) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2183915 | 0.88 | DPP7 (0.42) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2181939 | 0.88 | DPP7 (0.41) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2192847 | 0.86 | NPY4R (0.41) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL2190402 | 0.83 | NRP1 (0.40) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL30199162 | 0.83 | DPP4 (0.43) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL3451623 | 0.82 | ACE (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL1674799 | 0.82 | ACE (0.46) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL2114959 | 0.82 | ACE (0.46) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | PTGS2, PTGES2, PTGS1 | DPP4 2395/4885DPP7 1491/4885DPP8 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.